OAC2
Based on 1 publication(s) in Google Scholar
OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter.
For research use only. We do not sell to patients.
- Purity: 98.42%
- CAS No.: 6019-39-2
- Formula: C15H12N2O
- Molecular Weight:236.27
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) OAC2
More
Biological Activity
Octamer-binding transcription factor 4 (Oct4) is a master regulator of the induction and maintenance of cellular pluripotency, and has crucial roles in early stages of differentiation. It is the only factor that cannot be substituted by other members of the same protein family to induce pluripotency[1]. Oct4 has been shown to be an essential regulator of embryonic stem cell (ESC) pluripotency and key to the reprogramming process. OAC2 is a structural analog of OAC1. OAC2 activates both Oct4 and Nanog reporters to a similar extent as OAC1. OAC1 and its two structural analogs OAC2 and OAC3 enhances reprogramming efficiency fourfold, up to as high as 2.75%, and accelerates the appearance of iPSC colonies 3 to 4 d when used in combination with the four reprogramming factors, Oct4, Sox2, Klf4, and c-Myc[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 6019-39-2
-
Appearance Solid
-
Molecular Weight 236.27
-
Formula C15H12N2O
-
Color White to gray
-
SMILES
O=C(NC1=CC2=C(NC=C2)C=C1)C3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : ≥ 100 mg/mL (423.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 25 mg/mL (105.81 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (10.58 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (10.58 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
The Oct4-luc or Nanog-luc cells are treated with compound OAC1 or its structural analogs OAC2, OAC3 at 1 μM concentration or at indicated concentrations. Other compounds used include 2 μM BIO, 2 μM BIX, 2 μM 5'-azacytidine, 25 μg/mL Vitamin C, 10 nM Am580, 5 μM tranylcypromine, and 0.5 mM valporic acid. Luciferase reporter assays are performed 24 h after compound treatment or at indicated time points. For Topflash reporter assays, 0.2 μg β-catenin–responsive Topflash reporter gene plasmid is introduced into CV1 cells using trasfection. Compounds are added 6 h after transfection. Luciferase activity is measured 48 h after compound treatment using the Glo Luciferase Assay System[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Okuyama T, et al. Structural and mechanistic insights into nuclear transport and delivery of the critical pluripotency factor Oct4 to DNA. J Biomol Struct Dyn. 2017 Feb 6:1-50 [Content Brief]
[2]. Li W, et al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):20853-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 4.2324 mL | 21.1622 mL | 42.3245 mL | 105.8111 mL |
| 5 mM | 0.8465 mL | 4.2324 mL | 8.4649 mL | 21.1622 mL | |
| 10 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL | 10.5811 mL | |
| 15 mM | 0.2822 mL | 1.4108 mL | 2.8216 mL | 7.0541 mL | |
| 20 mM | 0.2116 mL | 1.0581 mL | 2.1162 mL | 5.2906 mL | |
| 25 mM | 0.1693 mL | 0.8465 mL | 1.6930 mL | 4.2324 mL | |
| 30 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.5270 mL | |
| 40 mM | 0.1058 mL | 0.5291 mL | 1.0581 mL | 2.6453 mL | |
| 50 mM | 0.0846 mL | 0.4232 mL | 0.8465 mL | 2.1162 mL | |
| 60 mM | 0.0705 mL | 0.3527 mL | 0.7054 mL | 1.7635 mL | |
| 80 mM | 0.0529 mL | 0.2645 mL | 0.5291 mL | 1.3226 mL | |
| 100 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0581 mL |